These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 16005196)

  • 21. Predicting the drug concentration in starch acetate matrix tablets from ATR-FTIR spectra using multi-way methods.
    Matero S; Pajander J; Soikkeli AM; Reinikainen SP; Lahtela-Kakkonen M; Korhonen O; Ketolainen J; Poso A
    Anal Chim Acta; 2007 Jul; 595(1-2):190-7. PubMed ID: 17606000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controlled release of saccharides from matrix tablets.
    Mäki R; Suihko E; Korhonen O; Pitkänen H; Niemi R; Lehtonen M; Ketolainen J
    Eur J Pharm Biopharm; 2006 Feb; 62(2):163-70. PubMed ID: 16343875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets.
    Hayashi T; Kanbe H; Okada M; Kawase I; Ikeda Y; Onuki Y; Kaneko T; Sonobe T
    Int J Pharm; 2007 Aug; 341(1-2):105-13. PubMed ID: 17512147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Saturated phosphatidylcholine as matrix former for oral extended release dosage forms.
    Kolbina M; Bodmeier R; Körber M
    Eur J Pharm Sci; 2017 Oct; 108():86-92. PubMed ID: 28716757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of sustained release fast-disintegrating tablets using various polymer-coated ion-exchange resin complexes.
    Jeong SH; Park K
    Int J Pharm; 2008 Apr; 353(1-2):195-204. PubMed ID: 18164882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Substituted amylose matrices for oral drug delivery.
    Moghadam SH; Wang HW; Saddar El-Leithy E; Chebli C; Cartilier L
    Biomed Mater; 2007 Mar; 2(1):S71-7. PubMed ID: 18458424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Temperature effects on the binding efficiency of starch pastes.
    Eradiri O; Nasipuri RN
    Pharmazie; 1985 Mar; 40(3):183-5. PubMed ID: 4023034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Formulation of a extended release tablet containing dexibuprofen.
    Yi HG; Chi MH; Kim YI; Woo JS; Park ES
    Arch Pharm Res; 2008 Dec; 31(12):1637-43. PubMed ID: 19099235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmaceutical granulation and tablet formulation using neural networks.
    Kesavan JG; Peck GE
    Pharm Dev Technol; 1996 Dec; 1(4):391-404. PubMed ID: 9552323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel fast disintegrating tablet fabricated by three-dimensional printing.
    Yu DG; Branford-White C; Yang YC; Zhu LM; Welbeck EW; Yang XL
    Drug Dev Ind Pharm; 2009 Dec; 35(12):1530-6. PubMed ID: 19929213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of sodium alginate as drug release modifier in matrix tablets.
    Liew CV; Chan LW; Ching AL; Heng PW
    Int J Pharm; 2006 Feb; 309(1-2):25-37. PubMed ID: 16364576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained release matrix tablets prepared from cospray dried mixtures with starch hydrophobic esters.
    Sakhnini N; Al-Zoubi N; Al-Obaidi GH; Ardakani A
    Pharmazie; 2015 Mar; 70(3):177-82. PubMed ID: 25980178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solubility and diffusion of nitrogen in maltodextrin/protein tablets.
    Schoonman A; Ubbink J; Bisperink C; Le Meste M; Karel M
    Biotechnol Prog; 2002; 18(1):139-54. PubMed ID: 11822912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous probing of swelling, erosion and dissolution by NMR-microimaging--effect of solubility of additives on HPMC matrix tablets.
    Tajarobi F; Abrahmsén-Alami S; Carlsson AS; Larsson A
    Eur J Pharm Sci; 2009 May; 37(2):89-97. PubMed ID: 19429415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pore shape in the sodium chloride matrix of tablets after the addition of starch as a second component.
    Wu YS; Frijlink HW; van Vliet LJ; van der Voort Maarschalk K
    Eur J Pharm Biopharm; 2008 Oct; 70(2):539-43. PubMed ID: 18582573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of critical polymer properties for polymer release and swelling of HPMC matrix tablets.
    Viridén A; Wittgren B; Larsson A
    Eur J Pharm Sci; 2009 Feb; 36(2-3):297-309. PubMed ID: 19038336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Citric acid monohydrate as a release-modifying agent in melt extruded matrix tablets.
    Schilling SU; Bruce CD; Shah NH; Malick AW; McGinity JW
    Int J Pharm; 2008 Sep; 361(1-2):158-68. PubMed ID: 18582547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro controlled release of sodium ferulate from Compritol 888 ATO-based matrix tablets.
    Li FQ; Hu JH; Deng JX; Su H; Xu S; Liu JY
    Int J Pharm; 2006 Nov; 324(2):152-7. PubMed ID: 16837152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preparation and characterization of starch-metal silicate Co-precipitates--evaluation as tablet superdisintegrant.
    Singh I; Kaur B; Juneja P
    Polim Med; 2014; 44(3):157-66. PubMed ID: 25696940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Roll compaction/dry granulation: effect of raw material particle size on granule and tablet properties.
    Herting MG; Kleinebudde P
    Int J Pharm; 2007 Jun; 338(1-2):110-8. PubMed ID: 17324537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.